<DOC>
	<DOC>NCT00644371</DOC>
	<brief_summary>To evaluate the use of ibritumomab tiuxetan (Zevalin) as part of the non myeloablative conditioning with melphalan, fludarabine and thiotepa in patients submitted to allogeneic transplantation of haematopoietic stem cells from family donor's peripheral blood.</brief_summary>
	<brief_title>Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. Written informed consent 2. Histologically confirmed Bcell lymphoma of the following subtypes: LBCDL Grade 3b follicular lymphoma Mantlecell lymphoma Transformed Bcell lymphoma Burkitt lymphoma in patients not eligible for a conventional allogeneic transplant 3. Highrisk Bcell CD20+ lymphoma defined by Having attained less than PR after two chemotherapy lines Posttransplantation relapse Presence of disease detected through a metabolic approach (PET/CT or else CT+PET) either before or after autologous transplantation Inability to collect enough stem cells for autologous transplantation 4. Stable disease at the time of transplantation 5. Age between 18 and 65 6. Performance status (ECOG) ≤ 2 7. Normal and suitable pulmonary function (DLCO ≥ 30%) 8. Left ventricular ejection fraction (LVEF) determined by ventriculography or echocardiogram ≥ 40% 9. Normal hepatic and renal function, with creatinine ≤ 2 mg/dl and Bi ≤ 1.5 mg/dl, and alkaline phosphatase ≤ 2.5 x UNL ; AST, ALT ≤ 2.5 x UNL (≤ 5 x UNL if hepatic infiltration) 1. Prior treatment with radiopharmaceutical agents 2. HIVassociated lymphoma 3. Presence of human antimouse antibodies (HAMA) or antichimeric antibodies (HACA) 4. Patient's inability to follow the protocol 5. Hypersensitivity to 90Yitritumomab tiuxetan 6. Presence of severe pathologies that preclude chemotherapeutic treatment 7. Pregnant women or pregnancy risk due to inappropriate contraceptive measures 8. Breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Allogeneic</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>GELTAMO</keyword>
	<keyword>Z-RIC</keyword>
</DOC>